New Developments in Cancer Treatment
One of the first questions after a cancer diagnosis is, “Which treatment is right for me?” Finding the answer begins with a multidisciplinary team of specialists working together. Medical oncologists, surgeons, radiation oncologists, pathologists and radiologists bring different perspectives to confirming the diagnosis, assessing how far the disease has spread and planning the sequence of treatment. The patient’s general health, daily life and preferences belong in that discussion too. [1] Pathological diagnosis remains essential to identifying the cancer type. Detailed molecular testing adds information about genetic changes that drive tumour growth and proteins that may guide treatment. For suitable patients, broad gene panels and other biomarker tests help explain why cancers arising in the same organ can behave differently. This allows treatment to be tailored to both the person and their tumour, although testing does not always identify a change that can be treated with an available medicine. [2] An important development in chemotherapy delivery is the antibody–drug conjugate (ADC). Its antibody recognises a particular target on cancer cells and carries an attached chemotherapy drug into them. Its uses are expanding: in 2026, datopotamab deruxtecan received US approval for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 immunotherapy. Targeted delivery does not eliminate side effects. [3,4] Biological agents and other targeted medicines also play an important role. Monoclonal antibodies and medicines that block growth signals inside cells can help control cancer when a suitable target is present. Molecular findings, previous treatments and the patient’s health guide the choice of medicine, its timing and whether it should be combined with another treatment. [3] In immunotherapy, anti-PD-1 and anti-PD-L1 antibodies block signals that prevent immune cells from attacking cancer. A newer approach, ivonescimab, is a bispecific antibody targeting both PD-1 and VEGF, which helps tumours develop blood vessels. Clinical studies continue. In November 2026, its US application for a particular lung cancer population previously treated with targeted therapy was not approved in its present form. [5,6] Other approaches draw on different parts of the immune system. Interleukin-15 (IL-15) is a signalling protein that supports T cells and natural killer (NK) cells. A medicine stimulating the IL-15 pathway is US-approved alongside BCG for certain BCG-unresponsive, non-muscle-invasive bladder cancers. NK cell therapies, including genetically engineered CAR-NK cells, are being evaluated in clinical trials. For each patient, the value of these advances lies in finding an appropriate option through an open discussion of its potential benefits and risks. [7,8] Sources [1] NCI · Tumour boards | [2] NCI · Molecular testing | [3] NCI · Targeted therapy | [4] FDA · ADC · 2026 | [5] NCI · Immunotherapy | [6] Summit · Ivonescimab · 15 Nov 2026 | [7] FDA · IL-15 | [8] MD Anderson · NK trials
Pathological diagnosis remains a key factor in determining the type of cancer. In addition, detailed molecular investigations explore gene changes that drive tumor growth and proteins that can guide treatment selection. In suitable patients, thanks to broad gene panels and other biomarker tests, we are better able to understand tumors that can behave differently even if they develop in the same organ. This allows us to plan treatment according to both the individual and the characteristics of the tumor; however, not every test result is expected to point to a usable drug. [2]
One of the significant advances in chemotherapy is antibody-drug conjugates (ADCs). In these drugs, the antibody recognizes a specific target on the cancer cell and delivers the chemotherapy attached to it to the cell. Their use is expanding: in 2026, datopotamab deruxtecan received approval in the US for adults with inoperable or metastatic triple-negative breast cancer who are not suitable for PD-1/PD-L1 immunotherapy. This targeted delivery does not mean that side effects are eliminated. [3,4]
Biological agents and other targeted drugs also play an important role in treatment. Monoclonal antibodies and drugs that inhibit intracellular growth signals can help control the disease when the appropriate target is found. Which drug, in what order, or in combination with which treatment is used is determined according to molecular results, previous treatments, and the individual's condition. [3]
In immunotherapy, anti-PD-1 and anti-PD-L1 antibodies remove certain signals that prevent immune cells from recognizing and acting against cancer. One of the newer approaches, ivonescimab, is a dual-specific antibody that targets PD-1 and VEGF, which plays a role in tumor vascularization, in the same molecule. Research is ongoing; a US regulatory application for a specific group of lung cancer patients who have previously received targeted therapy, dated November 2026, has not yet been approved in its current form. [5,6]
It is also possible to harness other strengths of the immune system. Interleukin-15 (IL-15) is a signaling protein that supports T cells and natural killer (NK) cells. A drug that stimulates the IL-15 pathway is approved in the US in combination with BCG for certain superficial bladder cancers that do not respond to BCG. NK and genetically modified CAR-NK cell therapies are being evaluated in clinical trials. The value of all these developments for the patient is to be able to find the option that suits them by discussing the expected benefits and risks together. [7,8]
Sources [1] NCI · Tumour boards | [2] NCI · Molecular testing | [3] NCI · Targeted therapy | [4] FDA · ADC · 2026 | [5] NCI · Immunotherapy | [6] Summit · Ivonescimab · 15 Nov 2026 | [7] FDA · IL-15 | [8] MD Anderson · NK trials
